Investigator Databank Expands Members and Launches Website
Novartis, Janssen, Merck (MSD outside the United States and Canada), Lilly, and Pfizer have joined with DrugDev in hosting a repository of specific investigator information as part of the Investigator Databank.
Novartis, Janssen, Merck (MSD outside the United States and Canada), Lilly, and Pfizer have joined with DrugDev in hosting a repository of specific investigator information as part of the Investigator Databank. In addition, investigators can now access the Investigator Databank through the launch of http://www.investigatordatabank.org. Through this website, investigators can securely log in, view and add to their information kept on file by the participating pharmaceutical companies or DrugDev.
The new website http://www.investigatordatabank.org enables the upload of standard essential documents such as CVs, GCP training certificates, and non-study specific site profile forms into a global repository, eliminating some of the repetitive, administrative tasks associated with study feasibility, site qualification, and site start-up.
With five member companies now on board, the Investigator Databank has grown to include nearly 180,000 investigators, 50,000 sites and 7,335 studies.
Read the full release here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
